HK1107001A1 - 抗整合素免疫綴合物，其製備方法和用途 - Google Patents

抗整合素免疫綴合物，其製備方法和用途

Info

Publication number
HK1107001A1
HK1107001A1 HK07112495.8A HK07112495A HK1107001A1 HK 1107001 A1 HK1107001 A1 HK 1107001A1 HK 07112495 A HK07112495 A HK 07112495A HK 1107001 A1 HK1107001 A1 HK 1107001A1
Authority
HK
Hong Kong
Prior art keywords
production
methods
immunoconjugates
integrin
integrin immunoconjugates
Prior art date
Application number
HK07112495.8A
Other languages
English (en)
Inventor
Qiming Chen
Mohit Trikha
Robert J Lutz
Rita M Steeves
Godfrey Amphlett
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HK1107001A1 publication Critical patent/HK1107001A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07112495.8A 2004-12-09 2007-11-15 抗整合素免疫綴合物，其製備方法和用途 HK1107001A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63444504P 2004-12-09 2004-12-09
PCT/US2005/043250 WO2006062779A2 (en) 2004-12-09 2005-11-30 Anti-integrin immunoconjugates, methods and uses

Publications (1)

Publication Number Publication Date
HK1107001A1 true HK1107001A1 (zh) 2008-03-28

Family

ID=36578407

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112495.8A HK1107001A1 (zh) 2004-12-09 2007-11-15 抗整合素免疫綴合物，其製備方法和用途

Country Status (25)

Country Link
US (2) US8603483B2 (zh)
EP (1) EP1819359B1 (zh)
JP (1) JP5421532B2 (zh)
KR (1) KR101281501B1 (zh)
CN (1) CN101193916B (zh)
AR (1) AR052041A1 (zh)
AU (1) AU2005314392B2 (zh)
BR (1) BRPI0515745A (zh)
CA (1) CA2591148A1 (zh)
DK (1) DK1819359T3 (zh)
EA (1) EA013323B1 (zh)
ES (1) ES2539126T3 (zh)
HK (1) HK1107001A1 (zh)
HU (1) HUE025449T2 (zh)
IL (1) IL183695A0 (zh)
MX (1) MX2007007011A (zh)
NO (1) NO20073493L (zh)
NZ (1) NZ555601A (zh)
PL (1) PL1819359T3 (zh)
PT (1) PT1819359E (zh)
SG (1) SG158119A1 (zh)
TW (1) TWI400087B (zh)
UA (1) UA94388C2 (zh)
WO (1) WO2006062779A2 (zh)
ZA (1) ZA200705556B (zh)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
JP5421532B2 (ja) * 2004-12-09 2014-02-19 セントカー・インコーポレーテツド 抗インテグリン免疫コンジュゲート、方法および使用
EP2216653A1 (en) 2005-08-02 2010-08-11 XBiotech, Inc Diagnosis, treatment and prevention of vascular disorders using il-1alpha autoantibodies
RS54156B1 (en) * 2006-03-21 2015-12-31 Genentech Inc. COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
ES2746925T3 (es) * 2006-08-03 2020-03-09 Medimmune Ltd Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
WO2008042611A2 (en) * 2006-09-29 2008-04-10 Centocor, Inc. Method of using il6 antagonists with mitoxantrone for prostate cancer
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
JP2011501656A (ja) 2007-09-26 2011-01-13 ジェネンテック， インコーポレイテッド 新規抗体
NO2281006T3 (zh) 2008-04-30 2017-12-30
ES2797126T3 (es) 2008-05-30 2020-12-01 Xbiotech Inc Usos de anticuerpos IL-1 alfa
CA2731384C (en) * 2008-07-21 2015-03-10 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
CN102209557A (zh) 2008-09-12 2011-10-05 埃克斯生物科技公司 靶向病原性单核细胞
EP2356457B1 (en) * 2008-10-13 2018-05-16 Xeptagen SPA Method for the preparation of immunoconjugates and use thereof
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
MX349210B (es) 2009-06-03 2017-07-18 Immunogen Inc Métodos de conjugación.
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
CA2676946A1 (en) * 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
CN107281488B (zh) * 2010-08-23 2021-02-09 詹森生物科技公司 对肿瘤疾病的治疗
PT2634194T (pt) * 2010-10-29 2018-10-19 Perseus Proteomics Inc Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
AR086363A1 (es) 2011-04-21 2013-12-11 Bayer Ip Gmbh Conjugados de principio activo-ligante (adc) y el uso de los mismos
BR112013028890A2 (pt) * 2011-05-09 2017-01-31 Univ Virginia Patent Foundation composições e métodos para o tratamento de câncer
CA2849710C (en) 2011-09-23 2020-04-28 Xbiotech Inc. Cachexia treatment
RU2623441C2 (ru) * 2012-01-27 2017-06-26 Ф.Хоффманн-Ля Рош Аг Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим альфа-v-бета-3
MX360141B (es) * 2012-02-17 2018-10-24 Seattle Genetics Inc Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
ES2716561T3 (es) 2012-09-26 2019-06-13 Immunogen Inc Métodos mejorados para la acilación de maitansinol
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US9180203B2 (en) * 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US10005838B2 (en) * 2013-07-19 2018-06-26 The Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
US20160354482A1 (en) 2013-08-26 2016-12-08 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
JP2017526682A (ja) * 2014-09-02 2017-09-14 イミュノジェン， インコーポレイテッド 抗体薬物複合体組成物の製剤化方法
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
AU2015358367B2 (en) 2014-12-04 2020-07-02 Celgene Corporation Biomolecule conjugates
KR102556153B1 (ko) 2014-12-23 2023-07-14 엔비이-테라퓨틱스 아게 안트라사이클린 유도체를 포함하는 결합단백질 약물 접합체
WO2016207089A1 (de) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017136623A1 (en) 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
US10639382B2 (en) 2017-04-13 2020-05-05 National Guard Health Affairs Method for treating leukemia
CN110869051A (zh) * 2017-05-30 2020-03-06 小利兰·斯坦福大学托管委员会 对神经炎症性疾病的治疗
JP2020523319A (ja) * 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド 免疫調節化合物の抗体コンジュゲートおよびその使用
US20200046737A1 (en) 2018-08-09 2020-02-13 Notable Labs, Inc. Methods for treating cancer, and compositions therefor
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
BR112022000337A2 (pt) 2019-07-10 2022-04-12 Cybrexa 2 Inc Conjugados de peptídeos de citotoxinas como terapêuticos
WO2024001669A1 (zh) * 2022-06-27 2024-01-04 昱言科技(北京)有限公司 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN115350187B (zh) * 2022-08-30 2023-08-29 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
AU3737893A (en) * 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JP3161490B2 (ja) 1993-07-30 2001-04-25 松下電器産業株式会社 金型装置
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
GB9909392D0 (en) * 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
EP2977063A1 (en) 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AR030612A1 (es) * 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2005525423A (ja) 2002-05-13 2005-08-25 スミスクライン・ビーチャム・コーポレイション メイタンシノールの調製方法
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7374762B2 (en) * 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
ES2863498T3 (es) 2003-05-20 2021-10-11 Immunogen Inc Agentes citotóxicos mejorados que comprenden nuevos maitansinoides
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP5421532B2 (ja) * 2004-12-09 2014-02-19 セントカー・インコーポレーテツド 抗インテグリン免疫コンジュゲート、方法および使用

Also Published As

Publication number Publication date
EP1819359A4 (en) 2010-04-28
UA94388C2 (ru) 2011-05-10
TWI400087B (zh) 2013-07-01
BRPI0515745A (pt) 2008-08-05
US20140093523A1 (en) 2014-04-03
NO20073493L (no) 2007-09-06
CA2591148A1 (en) 2006-06-15
ES2539126T3 (es) 2015-06-26
JP5421532B2 (ja) 2014-02-19
JP2008523062A (ja) 2008-07-03
US8603483B2 (en) 2013-12-10
SG158119A1 (en) 2010-01-29
US20060127407A1 (en) 2006-06-15
CN101193916A (zh) 2008-06-04
IL183695A0 (en) 2007-09-20
KR20070089220A (ko) 2007-08-30
DK1819359T3 (en) 2015-04-20
PT1819359E (pt) 2015-05-28
ZA200705556B (en) 2008-12-31
NZ555601A (en) 2009-07-31
TW200635606A (en) 2006-10-16
EA200701250A1 (ru) 2008-06-30
HUE025449T2 (en) 2016-04-28
EA013323B1 (ru) 2010-04-30
KR101281501B1 (ko) 2013-07-15
AR052041A1 (es) 2007-02-28
WO2006062779A3 (en) 2008-01-17
MX2007007011A (es) 2007-09-21
AU2005314392A1 (en) 2006-06-15
AU2005314392B2 (en) 2011-04-14
EP1819359B1 (en) 2015-03-18
WO2006062779A2 (en) 2006-06-15
EP1819359A2 (en) 2007-08-22
PL1819359T3 (pl) 2015-08-31
CN101193916B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
PL1819359T3 (pl) Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
EP2076326A4 (en) CE-ZR-R-O-CATALYSTS, ARTICLES WITH THE CE-ZR-R-O-CATALYSTS, AND METHOD FOR THE PRODUCTION AND USE OF THE CE-ZR-R-O-CATALYSTS
EP2046391A4 (en) DRUG VECTORS, THEIR SYNTHESIS, AND METHODS FOR THEIR USE
ZA200705951B (en) Hydroprocessing catalyst, preparation method thereof and use of same
ZA200710173B (en) Tygecycline and methods of preparing 9-nitrominocycline
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
IL189914A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
IL180284A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
EP1979269A4 (en) CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP1797186A4 (en) EXPRESSION SYSTEM, ITS COMPONENTS AND USE METHOD
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
IL181569A0 (en) Biotinylated hexadecasaccharides, preparation and use thereof
PL1683840T3 (pl) Odporne na redukcję pigmenty oparte na ferrycie cynkowym, sposób ich wytwarzania i ich zastosowanie
IL183136A0 (en) Modified alginates, methods of production and use
IL177759A0 (en) Cospeptin, cosmedin and their uses
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
HK1107340A1 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
ZA200608279B (en) Synthetic chemokines, methods of manufacture, and uses

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM JANSSEN BIOTECH INC. TO JANSSEN BIOTECH, INC..

Effective date: 20111116

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191130